These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31919749)

  • 1. Adefovir Dipivoxil plus Chinese Medicine in HBeAg-Positive Chronic Hepatitis B Patients: A Randomized Controlled 48-Week Trial.
    Li XK; Zhang MX; Shao FZ; Zhou DQ; Xue JD; Liu TJ; Chi XL; Lu BJ; Wang XB; Li Q; Li J; Mao DW; Yang HS; Yang HZ; Zhao WX; Li Y; Zhang GL; Zhao YM; Zou JD; Liu MY; Zhang KK; Yang XZ; Gan DN; Li Y; Zhang P; Li ZG; Li S; Ye YA
    Chin J Integr Med; 2020 May; 26(5):330-338. PubMed ID: 31919749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial.
    Ye YA; Li XK; Zhou DQ; Chi XL; Li Q; Wang L; Lu BJ; Mao DW; Wu QK; Wang XB; Zhang MX; Xue JD; Li Y; Lu W; Guo JC; Jiang F; Zhang XW; Du HB; Yang XZ; Guo H; Gan DN; Li ZG
    Chin J Integr Med; 2018 Sep; 24(9):653-660. PubMed ID: 30209792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
    Ling N; Zhou Z; Zhang DZ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
    J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients].
    Liu Y; Liu L; Peng D; Li W; Du Y; Jia T; Chang L; Li H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Mar; 22(3):181-4. PubMed ID: 24824118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B.
    Zeng M; Mao Y; Yao G; Wang H; Hou J; Wang Y; Ji BN; Chang CN; Barker KF
    Hepatology; 2006 Jul; 44(1):108-16. PubMed ID: 16799983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B].
    Lin XH; Si CW; Yu YY; Li J; Chen XY; Ren XM; Liu P; Zhang SL; Kang XP
    Zhonghua Gan Zang Bing Za Zhi; 2006 Dec; 14(12):898-901. PubMed ID: 17196132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B].
    Zhao H; Zhang YX; Chen XY; Wang L; Tang XP; Si CW
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):294-7. PubMed ID: 17637268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study on Baihua Xianglian detoxification recipe combined with adefovir dipivoxil in treating HBeAg positive chronic hepatitis].
    Qiu H; Mao DW; Wei AL
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Feb; 32(2):176-9. PubMed ID: 22574587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
    Hou JL; Gao ZL; Xie Q; Zhang JM; Sheng JF; Cheng J; Chen CW; Mao Q; Zhao W; Ren H; Tan DM; Niu JQ; Chen SJ; Pan C; Tang H; Wang H; Mao YM; Jia JD; Ning Q; Xu M; Wu SM; Li J; Zhang XX; Ji Y; Dong J; Li J
    J Viral Hepat; 2015 Feb; 22(2):85-93. PubMed ID: 25243325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
    Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy.
    Wang LC; Chen EQ; Cao J; Liu L; Wang JR; Lei BJ; Tang H
    J Viral Hepat; 2010 Mar; 17(3):178-84. PubMed ID: 19656287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir
    Rodríguez M; Pascasio JM; Fraga E; Fuentes J; Prieto M; Sánchez-Antolín G; Calleja JL; Molina E; García-Buey ML; Blanco MÁ; Salmerón J; Bonet ML; Pons JA; González JM; Casado MÁ; Jorquera F;
    World J Gastroenterol; 2017 Nov; 23(41):7459-7469. PubMed ID: 29151700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Short-term efficacy of adefovir dipivoxil as an add-on therapy in the pegylated IFNalpha-2a treatment for HBeAg positive chronic hepatitis B patients].
    Chen LB; Shu X; Jie YS; Yang XA; Zhang K; Li G; Xu QH
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Feb; 24(1):39-41. PubMed ID: 20848847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.
    Hui CK; Zhang HY; Bowden S; Locarnini S; Luk JM; Leung KW; Yueng YH; Wong A; Rousseau F; Yuen KY; Naoumov NN; Lau GK
    J Hepatol; 2008 May; 48(5):714-20. PubMed ID: 18207280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy.
    Tseng KC; Cheng PN; Wu IC; Chang CK; Chou AL; Liu WC; Chang TT
    Hepatogastroenterology; 2009; 56(91-92):813-8. PubMed ID: 19621708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.